CLPT, US18507C1036

ClearPoint Neuro stock: ATM offering cap raised to $150 million

Published on 11/19/2026 at 01:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
ClearPoint Neuro stock faces a larger potential equity supply after the company lifted its ATM sales cap. The current prospectus still covers about $27.5 million.

Capital access expands under revised agreement

  • ClearPoint Neuro can decide whether and when to sell additional shares through Stifel.
  • The existing prospectus capacity remains unchanged by the agreement amendment.
  • The company develops navigation and delivery systems for brain and spine therapies.
CLPT, US18507C1036, Illustration mit AI erstellt.

ClearPoint Neuro amended its at-the-market equity offering agreement with Stifel on November 18, 2026, increasing the aggregate sales-proceeds limit from $50 million to $150 million. The filing said the higher limit includes sales made under the original agreement.

The SEC filing reproduced by StockTitan said ClearPoint Neuro had sold approximately $22.5 million of shares under the original program as of November 18. The amount available under the existing prospectus supplement remained approximately $27.5 million, so the amendment raised the agreement ceiling without increasing that currently available amount.

Flexible funding, potential dilution

ClearPoint Neuro is not required to sell shares under the agreement and can suspend offers. Stifel may receive a commission of up to 3.0% of gross sales proceeds, while the company retains control over the timing, price and size of sales.

For investors, the revised agreement increases ClearPoint Neuro's potential access to equity financing. Any future share sales could provide capital for operations, research and development, clinical programs or commercial activity, while also increasing the potential supply of common stock.

Brain and spine therapy platform

ClearPoint Neuro develops technologies that enable precise navigation to the brain and spine. Its portfolio combines established clinical products with preclinical development services for controlled drug and device delivery.

The company serves healthcare and research centers across North America, Europe, Asia and South America. Its specialized focus is on enabling neurosurgical procedures and cell and gene therapy delivery rather than operating as a broad medical-device supplier.

ClearPoint Neuro company facts

  • Company: ClearPoint Neuro, Inc.
  • Ticker: CLPT
  • Exchange: Nasdaq Capital Market
  • Sector: Healthcare
  • Industry: Medical devices
  • Headquarters: Solana Beach, California

The broader U.S. equity market can be followed in the S&P 500 market environment.

More news and analyses on ClearPoint Neuro stock are available here.

Disclaimer...
en | US18507C1036 | CLPT | boerse | 70533206 | bgmi